期刊
ANNALS OF HEMATOLOGY
卷 88, 期 7, 页码 629-632出版社
SPRINGER
DOI: 10.1007/s00277-008-0650-1
关键词
Ph(neg)cMPD; JAK2V617F; Hydroxyurea
类别
Ph-negative chronic myeloproliferative disorders (Ph(neg)cMPD) are treated according to the estimated vascular risk. The recent discovery of V617F point mutation of the JAK2 kinase, which frequently occurs in these diseases, has not changed their management so far. However, emerging data tend to support a prothrombotic role for the mutation, along with a better response of JAK2V617F mutated patients to hydroxyurea treatment. Our data further support this notion.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据